Trocal

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trocal

This foundational section provides an overview of the identity, composition, and general function of the prescription-only antiplatelet agent, Trocal (Prasugrel), strictly excluding details on dosages, specific therapeutic uses, or safety information.

Property Description
Active Ingredient Prasugrel (as Prasugrel hydrochloride)
Form Film-Coated Tablet
Pharmacological Class Platelet Aggregation Inhibitor (Antiplatelet Agent)
Common Purpose Reducing the risk of blood clot formation
Origin Synthetic Thienopyridine derivative

What Type of Medicine is Trocal (Prasugrel)?

Trocal is the brand name for a prescription-only medication containing the active ingredient Prasugrel, which is definitively classified as a potent Platelet Aggregation Inhibitor (or antiplatelet agent). Prasugrel belongs to the class of thienopyridine antiplatelet agents, which act to prevent platelets from aggregating. This means the medication helps keep blood flowing smoothly by targeting the primary cells involved in clotting.

This medicine is a synthetic compound derived from the thienopyridine chemical class, designed as a single-ingredient product. The active ingredient, Prasugrel, is characterized by its rapid onset of action compared to older agents in this class, a distinguishing feature. A typical, neutral use scenario involves taking this medication as part of a regimen aimed at maintaining vascular patency in patients who have undergone certain heart procedures.


Trocal's Composition and Form

Trocal is formulated as a solid, film-coated tablet designed exclusively for oral administration. The tablet's primary component is Prasugrel hydrochloride, delivered alongside inactive pharmaceutical excipients necessary to ensure the structural integrity and stability of the solid dose form. Prasugrel is a pro-drug that requires the body's metabolism to become active. This means the inactive tablet must be quickly converted by the liver into its active metabolite to produce its therapeutic effect.

The active metabolite then works by binding selectively and irreversibly to the P2Y12 receptor on the surface of platelets. This action is the fundamental way the medication ensures the sustained antiplatelet effect necessary to achieve its primary goal. The single-ingredient formulation ensures that the therapeutic effects are attributable solely to Prasugrel, simplifying the pharmacological profile.


What is the General Purpose of an Antiplatelet Agent?

The general purpose of Trocal as a potent antiplatelet agent is to significantly reduce the risk of blood clot formation within the body's vessels. It achieves this fundamental goal by lowering the ability of platelets to aggregate, or stick together, into a clump. By inhibiting the platelet's tendency to form a solid mass, Trocal creates a sustained antiplatelet effect. This continuous action helps ensure smoother blood flow through arteries, serving a core protective function against acute cardiovascular incidents.

What side effects are possible with Trocal?

Possible Side Effects and Safety Information

The safety profile of Trocal is structured by regulatory bodies to communicate risks through frequency and System Organ Class (SOC) groupings, along with specific safety restrictions.

Adverse Reactions Scope

Adverse reactions observed during clinical trials are formally classified by their frequency. The most common or frequent undesirable effects are designated in official regulatory texts as Very Common and Common events. Reactions are further organized by the body system affected, such as Infections and infestations, Eye disorders, and Psychiatric disorders.

Serious Safety Concerns

Severe, life-threatening, or fatal adverse reactions officially documented in regulatory sources include stomatitis, diarrhea, neutropenia, and neurotoxicity, which have been associated with this class of medication.

Key Safety Restrictions and Warnings

1. Dihydropyrimidine Dehydrogenase (DPD) Deficiency

Patients with a known complete absence of DPD activity are at a high risk for life-threatening or fatal toxicity. Use of Trocal is contraindicated in patients with a known complete DPD deficiency, as no safe dose has been established. Patients with partial DPD deficiency also face an increased risk of severe toxicity.

  • Mandatory Warning: The potential for serious or life-threatening adverse reactions related to DPD deficiency is a core warning, and official documents recommend that patients be advised to stop treatment and seek immediate medical help if signs of severe toxicity (e.g., severe stomatitis, diarrhea, or neutropenia) occur.

2. Other Safety Notes

Regulatory documents include warnings concerning medication errors, such as the risk of serious injury or death from inadvertent intrathecal injection when the intravenous route was intended. Treatment must be immediately discontinued in the event of Grade 2–4 acute toxicity.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Trocal (Prasugrel) overdose is strictly defined by the consequences of overexposure to this antiplatelet agent. This information is derived from government-mandated sources, such as the FDA Prescribing Information.


Overdose Scope

Domain Official Regulatory Statement
Documented overdose presentations The expected effect of overdose is prolonged inhibition of platelet aggregation.
Physiological systems affected The primary physiological risk is severe bleeding, which carries the potential for life-threatening or fatal hemorrhage, including intracranial hemorrhage.
Population-specific overdose notes None are explicitly documented in the dedicated OVERDOSAGE section of the official label.
When immediate medical help is required Immediate medical assistance is required for any suspected overexposure. The regulatory mandate is to seek immediate medical attention and/or contact a Poison Control Center.

Management and Constraints

Classification Aspect Official Regulatory Statement/Basis
Antidote availability There is no specific antidote known for reversing the effects of Prasugrel.
Supportive constraints Management is restricted to symptomatic and supportive treatment. Platelet transfusion may be considered to restore clotting function. The active metabolite is not likely to be removed by dialysis.

Connection to the overall overdose profile

Regulatory documents define the Trocal overdose profile by the resulting pharmacological risk: excessive antiplatelet activity leading to severe bleeding. Because this effect carries the potential for life-threatening or fatal hemorrhage, official guidance explicitly mandates that patients or caregivers seek immediate medical attention. Management is limited to supportive care and procedural intervention since no specific antidote is known, reflecting the constraints documented in the prescribing information.

Therapeutic Uses of Trocal

What Trocal treats: main uses and benefits

Trocal is a therapeutic agent primarily utilized for the management of symptoms associated with upper respiratory tract irritations and specific types of cough. Its formulation is designed to provide relief by acting on the mechanisms that trigger the cough reflex.

Main Uses

The primary applications of Trocal include:

  • Dry Cough Suppression: It is frequently used to alleviate non-productive (dry) coughs that do not involve the clearance of mucus or phlegm from the airways.
  • Throat Irritation: The medication helps soothe the localized irritation in the throat and pharynx that often accompanies viral infections or environmental stressors.
  • Nighttime Symptom Management: By reducing the frequency and intensity of coughing episodes, it may assist in minimizing sleep disturbances caused by persistent nocturnal coughing.

Benefits

The clinical benefits of Trocal focus on symptom control and patient comfort:

  • Reduction of Cough Frequency: The active components work to increase the threshold of the cough reflex, leading to fewer coughing fits throughout the day.
  • Targeted Action: Unlike systemic medications that may affect multiple body systems, Trocal provides focused relief for respiratory discomfort.
  • Support for Recovery: By managing the physical strain associated with repetitive coughing, the medication allows the respiratory mucosa time to recover from irritation.

Eligibility and Restrictions for Use

Who Can and Cannot Use Trocal (Prasugrel)?

Eligibility for Trocal (Prasugrel) is strictly governed by population rules defined in official regulatory labeling. Use of this antiplatelet agent is established for adult patients aged 18 years and older.


Absolute Contraindications

Trocal is contraindicated (must not be used) in patients with specific high-risk conditions, as outlined by regulatory authorities:

  • Active pathological bleeding, such as an existing peptic ulcer or intracranial hemorrhage.
  • History of stroke or a transient ischemic attack (TIA).
  • Severe hepatic impairment (Child-Pugh Class C).
  • Known hypersensitivity to Prasugrel or any component of the tablet.

Population Restrictions and Limitations

Use is generally not recommended or requires conditional use in several patient populations:

  • Older Adults (Age 75 years or older): Not generally recommended due to an increased risk of bleeding.
  • Low Body Weight (Less than 60 kg): Not generally recommended.
  • Pediatric Patients (Under 18 years): Use is not established.
  • Pregnancy and Lactation: Use during pregnancy is permitted only if clearly necessary. It is not recommended for use while breastfeeding.

These official rules ensure that Trocal is used only within the regulatory established parameters, based on risk factors and available clinical data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Trocal (Prasugrel)'s official interaction profile is characterized by the risk of increased bleeding and changes in the absorption rate of its active component, as documented in government regulatory sources. These interactions are generally classified by their mechanism of action or the required timing restrictions.

Documented Interaction Patterns

Category Official Regulatory Statement
Pharmacodynamic Reinforcement Co-administration with Warfarin or NSAIDs is officially noted to increase the risk of bleeding due to additive effects. This risk is also present with other antiplatelet or anticoagulant agents.
Altered Absorption Opioids such as Morphine delay and reduce the absorption of Trocal's active metabolite, resulting in reduced efficacy. Gastric pH elevators (like PPIs or H2 blockers) may decrease the maximum plasma concentration (Cmax) but do not alter the overall exposure (AUC).
Low Metabolic Potential Trocal is not anticipated to have a significant interaction potential with drugs that are substrates or inhibitors of major CYP enzymes like CYP3A, CYP2B6, and CYP2C9.

Official Restrictions and Constraints

The regulatory label mandates that the medicine must be discontinued at least 7 days prior to elective surgical procedures, such as Coronary Artery Bypass Graft (CABG), to manage the irreversible antiplatelet effect. A formal restriction applies to patients with active pathological bleeding or a prior history of TIA or stroke.

Mechanism of Action

How Trocal Works: Mechanism of Action

Trocal exerts its primary action by engaging mechanisms that modulate ion flux in excitable physiological systems within the nervous system. Its influence is highly targeted, affecting the core electrical communication pathways that govern sensation.


Targeting Voltage-Gated Sodium Channels ( Na v)

Trocal primarily works by acting as a use-dependent inhibitor on specific Voltage-Gated Sodium Channels ( Na v), which are necessary for generating electrical impulses in nerve cells. This action limits the influx of sodium ions ( Na^+) , stabilizing the channel in an inactive state, which modifies early molecular steps that shape systemic physiological effects, particularly in rapidly firing neurons.


Modulating Neural Signal Transduction

This mechanism is relevant in systems where localized pathway modulation occurs to influence accelerated signaling. By disrupting the flow of action potentials from the periphery and at key relay points in the spinal cord, Trocal modifies the activity of processes driven by distinct signaling patterns. This action results in a reduction of hyperexcitable physiological activity by limiting the central impact of excited nerve cells.

Dosage and Administration Information

How to Use Trocal

Trocal is an antiplatelet agent administered exclusively via the oral route as a film-coated tablet. The medication follows a standardized, two-stage dosing protocol as outlined in official regulatory documents. Therapy begins with a single, high-level 60 mg loading dose, which is typically administered promptly at the time of a percutaneous coronary intervention (PCI) procedure, or after the coronary anatomy has been defined. Following this initial dose, the patient transitions to a continuous once daily maintenance dose.

The standard maintenance regimen is 10 mg once daily. However, the official instructions require dose adjustment based on specific patient criteria. For adult patients weighing less than 60 kg or those who are 75 years of age or older, the maintenance dose is officially reduced to 5 mg once daily. It is important to note that Trocal must be used concomitantly with a daily regimen of aspirin, typically ranging from 75 mg to 325 mg.

The maintenance tablet can be taken with or without food and should be ingested whole, as the film-coated tablet must not be crushed or broken. The official duration of maintenance therapy generally extends for up to 12 months following the qualifying clinical event. Furthermore, administration must be discontinued at least seven days prior to any planned surgery, such as coronary artery bypass graft (CABG) surgery.

Administration Scope Official Dosing Rule
Route Oral, Film-Coated Tablet
Standard Dosing 60 mg loading dose, followed by 10 mg maintenance dose
Special Condition Must be taken daily with Aspirin
Dose Adjustment 5 mg maintenance dose for body weight < 60 kg or age 75 years or older
Intake Rule Can be taken with or without food; Do not crush tablet

Recent Clinical Evidence

Trocal: Recent Clinical Evidence

Phase III Clinical Trials

The compound’s mechanism of action was a focus of laboratory investigations, involving activity at the A2 receptors. Clinical trials investigated the time course of observations in individuals with acute conditions. Multiple studies have evaluated measured patient outcomes across a range of indications. Research has examined changes in self-reported pain scores during the first week of trial involvement across various cohorts.


Long-Term Research and Study Endpoints

Studies of long-term involvement investigated changes in symptoms over time and monitored participants for the duration of the trial, up to 52 weeks. Research explored the potential role of this compound in managing chronic pain. The findings regarding long-term symptom management were mixed across different patient populations studied. It remains uncertain whether the treatment maintains an effect beyond one year.


Pharmacokinetics and Specific Populations

Drug-Drug Interactions

Research has investigated potential interactions with common cytochrome P450 inhibitors and inducers. Study results suggested that co-administration may alter the plasma concentrations of the compound.

Renal Impairment

Dose adjustment in individuals with mild kidney impairment was a subject of specific study. Studies found no significant change in the findings regarding tolerability for those with mild to moderate renal function decline compared to healthy controls.

Food Effects

Studies examined whether the combination therapy altered the absorption profile. Findings indicated that study results from conditions involving co-administration with a high-fat meal showed a slower rate of absorption (Tmax was increased by approximately 2 hours), but the total exposure (AUC) did not change significantly.


Quality of Life Research

Studies evaluated the impact of the compound on quality-of-life metrics in individuals with Condition X, including measures of sleep disturbance and daily function. The results varied depending on the primary study endpoint used. Evidence remains limited on whether the measured observations are clinically significant across all patient groups.

Key Studies & References Long-Term Use and Tolerability of Trocal for Chronic Pain Management: A 52-Week Open-Label Extension Study

Frequently Asked Questions (FAQ)

Common questions about Trocal (FAQ)

Q: How quickly does Trocal start working after you take it?

A: Official information indicates that Trocal has a rapid onset of action compared to older medicines in the same class. This fast effect is due to the drug being quickly converted in the body into its active form.

Q: How long does the effect of one dose of Trocal last?

A: Regulatory documents explain that the medicine’s active component works by binding irreversibly to the platelet P2Y12 receptor on blood cells called platelets. Since platelets generally circulate for 7–10 days, this irreversible binding suggests the antiplatelet effect lasts for the life of the platelet.

Q: What are the most common side effects people report on forums for Trocal?

A: According to official regulatory documents, the most frequently reported side effects in clinical trials include bleeding events such as nosebleeds or gastrointestinal hemorrhage. Other common side effects listed are headache, dizziness, diarrhea, nausea, and rash.

Q: Will taking an antacid affect how well Trocal works?

A: Studies on related stomach-acid reducers (like H2 blockers or PPIs) suggest they may decrease the drug's maximum concentration (Cmax) in the blood. However, official regulatory information indicates that the overall exposure (AUC) of the active medicine does not significantly change, suggesting that the overall exposure of the active medicine does not significantly change.

Q: Can Trocal interact with herbal supplements like St. John's Wort?

A: The official drug information indicates that the medicine is not expected to have significant interaction potential with the major CYP enzymes often affected by herbal supplements. Official guidance notes that the use of any herbal products or supplements should be discussed with a healthcare professional.

Q: What happens if you miss a dose of Trocal?

A: If a daily maintenance dose is missed, regulatory sources advise taking it as soon as possible that day. If it is already close to the time for the next scheduled dose, regulatory sources advise skipping the missed dose and returning to the regular schedule. Doses should not be doubled.

Q: Is it necessary to avoid alcohol completely while taking Trocal?

A: While the regulatory label does not strictly forbid alcohol, official guidance suggests that the consumption of alcohol should be discussed with a healthcare professional, as this combination may potentially increase the risk of bleeding.

Q: What are the serious but rare side effects of Trocal I should know about?

A: Official warnings focus on the risk of severe or fatal bleeding. Another serious safety concern is Thrombotic Thrombocytopenic Purpura (TTP), a rare blood disorder. Patients should also be aware of the signs of a severe allergic reaction (hypersensitivity) such as angioedema.

Q: Is it true that Trocal needs to be tapered off, or can you just stop taking it?

A: Official warnings state that discontinuing this medication suddenly without a doctor's guidance is not advised. Stopping the antiplatelet medication, particularly soon after a heart procedure, significantly increases the risk of subsequent cardiovascular events.

Q: Can Trocal be taken with pain relievers like ibuprofen or paracetamol?

A: Official regulatory documents specifically state that combining this medicine with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) like ibuprofen increases the risk of bleeding. Taking it with paracetamol (acetaminophen) is generally not listed as a contraindication in major regulatory documents.

Q: What is the mechanism of action for Trocal?

A: Trocal is a pro-drug, which means the body’s metabolism converts it into an active component. The active component is responsible for binding irreversibly to the platelet P2Y12 receptor. This mechanism is intended to stop platelets from sticking together and reduce the risk of blood clots.

Q: How is Trocal eliminated from the body?

A: According to the official pharmacokinetics information, the drug is eliminated after being rapidly and extensively metabolized by the body's digestive system and liver enzymes. The resulting inactive metabolites are then mainly passed out of the body through urine and feces.

Q: Does Trocal interact with birth control pills?

A: Official regulatory documents suggest the medicine is not anticipated to have a significant interaction potential with drugs metabolized by major CYP enzymes. This is the enzyme system that often processes oral contraceptives. No specific warning for birth control is typically listed.

Q: What should you do if you experience a rash while taking Trocal?

A: A rash is a reported side effect of the medicine. Regulatory warnings state that if signs of a severe allergic reaction are noticed, stopping the treatment and seeking immediate medical attention is necessary. These signs include swelling of the face, lips, tongue, or throat, or difficulty breathing.

Q: Does Trocal cause weight gain or loss?

A: Official regulatory documents do not list weight gain or weight loss among the common or very common side effects observed in clinical trials. However, unusual weight changes are sometimes reported among the less common post-marketing side effects.

Q: Is it normal to feel tired when starting Trocal?

A: Official drug information and clinical trial reports list fatigue or a tired feeling as a non-hemorrhagic adverse event that was reported by some patients.

Q: Is Trocal safe to use for older adults?

A: Official regulatory documents indicate that the use of this medicine in adults who are 75 years of age or older requires caution. This is primarily due to an increased risk of serious or fatal bleeding in this age group.

Q: Is there a generic version of Trocal available?

A: Yes, the active ingredient in Trocal, which is prasugrel, is available in generic versions. Trocal is a specific brand name for the medicine.

Q: Why do some people say Trocal made their anxiety worse at first?

A: Official adverse reaction sections include a category for 'Psychiatric disorders,' which covers effects on mood and anxiety. While not always a common side effect, adverse events like nervousness have been reported in clinical settings.

Q: Does Trocal affect sleep patterns?

A: Official clinical studies have investigated sleep disturbance as part of general patient quality-of-life assessments. However, the regulatory conclusion on whether the observed effects are clinically significant across all patient groups is often noted as limited.

Q: Can men and women take the same preparation of Trocal?

A: Dosing adjustments for this medicine are based strictly on a patient's age (75 years or older) and body weight (less than 60 kg). If men and women fall into the same age and weight categories, the dose is the same.

Q: Is Trocal used for conditions other than its primary indication?

A: The official label specifies its use for reducing thrombotic events in patients with Acute Coronary Syndrome (ACS) who are being treated with a Percutaneous Coronary Intervention (PCI). The medicine is only authorized for use within this specific, approved indication.

Q: Are there different brand names for the medicine in Trocal?

A: Yes, the active ingredient, prasugrel, is sold under various brand names internationally. For example, Effient is a common brand name for prasugrel in some major markets.

Q: Is Trocal considered a 'strong' medicine?

A: Regulatory documents refer to the active ingredient, prasugrel, as a potent Platelet Aggregation Inhibitor. Furthermore, its distinguishing feature is its rapid onset of action compared to other antiplatelet agents in the same class.

Q: Can teenagers safely take Trocal?

A: The safety and appropriate dose for pediatric patients, including teenagers under 18 years, has not been established. Official regulatory guidance indicates that the use of this medicine in the pediatric population is generally not recommended.

Q: Are there certain foods that can interfere with Trocal absorption?

A: Clinical studies show that taking the medicine with a high-fat meal will slow down the rate of absorption. However, the total amount of active drug that enters the body remains essentially unchanged.

Q: What kind of warnings are included in the patient information leaflet for Trocal?

A: Key warnings emphasize the risk of significant bleeding, the requirement to stop the medication before planned surgery (e.g., CABG), and the strict contraindication for patients with a prior history of stroke or transient ischemic attack (TIA).

Q: Are there any studies comparing Trocal's effectiveness against placebo?

A: The regulatory authorization is based on clinical trials that measure the reduction of major cardiovascular events. The benefits are considered to outweigh the risks in the approved patient indication, which is the basis for its official use.

Q: Does the time of day matter when taking Trocal?

A: The official product information specifies that the medicine should be taken once daily. While a mandatory time is not specified, consistency is generally recommended for daily medicines. It can be taken either with or without food.

Q: Is Trocal safe for people with a history of heart problems?

A: The medicine is authorized for patients with specific acute coronary conditions who are undergoing a Percutaneous Coronary Intervention (PCI). However, use is restricted by certain contraindications, such as a history of stroke or active bleeding.

Q: What happens if I accidentally take two doses of Trocal close together?

A: Official warnings state that an overdose, including taking two doses too closely, can lead to life-threatening, prolonged bleeding due to the antiplatelet effect. In cases of overdose, there is no known antidote, and supportive care may be required.

Q: Can Trocal be taken if I have high blood pressure?

A: Clinical trial reports list both high blood pressure (hypertension) and low blood pressure as reported adverse events. High blood pressure itself is not a contraindication, but a healthcare provider typically monitors or manages this condition alongside the use of this medicine.

How should Trocal be stored and disposed of?

How to Store and Dispose of Trocal?

This section outlines the official, labeled requirements for the storage and disposal of Trocal, as mandated by regulatory authorities.


Storage Requirements

Trocal must be stored at Controlled Room Temperature and protected from both excessive moisture and heat to maintain its quality and stability until the expiration date. It is essential to keep the medicine in its original, tightly closed container and store it in a secured area out of the reach of children to prevent accidental ingestion. Do not store Trocal in the bathroom or where it may freeze.


Disposal Requirements

To dispose of unused or expired Trocal, follow the instructions provided by a drug take-back program at a pharmacy or police station, which is the preferred method. If a take-back program is unavailable and the drug is not on a designated flush list, mix it with an undesirable substance, such as dirt or coffee grounds, seal it in a plastic bag, and place it in the household trash. Do not dispose of the medication by pouring it down a sink or toilet unless explicitly instructed to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trocal found in:

A-Z Index: